BioWorld - Sunday, September 15, 2024 Breaking News: BioWorld celebrates nine wins at 2024 APEX Awards See today's BioWorld Science Home » New TGF-β receptor type-1 inhibitors revealed in Chiesi ...
Over the past few decades, the idea of modifying a patient’s own immune cells to recognize and destroy cancer has evolved from concept to reality. So-called “adoptive T cell therapy” has emerged as ...
Chiesi Farmaceutici SpA has divulged TGF-β receptor type-1 (TGFBR1; ALK5; SKR4; TβR-I) inhibitors reported to be useful for the treatment of idiopathic pulmonary fibrosis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results